Peripheral T cell lymphoma: clinical utility of romidepsin
Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant...
Main Authors: | Sawey K, Zain J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-06-01
|
Series: | Blood and Lymphatic Cancer : Targets and Therapy |
Online Access: | http://www.dovepress.com/peripheral-t-cell-lymphoma-clinical-utility-of-romidepsin-a10099 |
Similar Items
-
Romidepsin in the treatment of cutaneous T-cell lymphoma
by: Jain S, et al.
Published: (2011-04-01) -
Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma
by: Claudius Irlé, et al.
Published: (2016-01-01) -
Romidepsin Used as Monotherapy in Sequence with Allogeneic Stem Cell Transplant in a Patient with Peripheral T-Cell Lymphoma
by: Nicholas Finn, et al.
Published: (2014-01-01) -
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
by: Francine Foss, et al.
Published: (2016-03-01) -
Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma
by: Balaji Jothishankar, MD, et al.
Published: (2020-12-01)